Home » Business » Cipla's petition against drug price revision rejected
DoP said since the company had not informed whether the price fixed had been implemented, there was no question of a review. It has asked the regulator to recover if there is any amount overcharged by the firm on sales of the drug.
“Based on the record note of discussions of the personal hearing and other records available in the file, the reviewing authority has decided that the review application of the petitioners may be rejected,” DoP said in its order.
The review petition was filed by Cipla against an NPPA pricing order of October 2010. The pricing authority, through its order, had capped the price of Cipla’s Dytor Plus tablets, which contains spironolactone and torsemide. According to an official, spironolactone is under government’s
Nifty soars 94 points, ends shy of 5,800
Market close near day highs on strong global cues
Drug makers charged with overcharging of Rs 2,362 cr
Musharraf arrested from farmhouse, in police custody now
Markets end lower on weak global cues